◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

CanSino Biologics Inc. (6185) Financial History

Name: CanSino Biologics Inc. (6185) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

CanSino Biologics Inc. (6185) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Tianjin, China with about 1,134 employees. Its market capitalization is roughly CNY 6 billion. In the fiscal year ended 2025-12-31, 6185 reported CNY 1.1B in revenue and CNY 28M in net income.

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides.

Interactive charts & full statements →

6185 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 1.1B	CNY 825M	CNY 345M	CNY 1.0B
Gross Profit	CNY 799M	CNY 580M	(CNY 876M)	(CNY 187M)
Operating Income (EBIT)	CNY 27M	(CNY 342M)	(CNY 2.1B)	(CNY 1.4B)
Net Income	CNY 28M	(CNY 379M)	(CNY 1.5B)	(CNY 909M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6185 Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	—	—	(CNY 4M)	(CNY 194M)	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6185 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 7.2B	CNY 8.0B	CNY 9.3B	CNY 11.5B	—
Total Liabilities	CNY 2.2B	CNY 3.0B	CNY 4.0B	CNY 4.2B	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6185 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

APTX · Apotex Health Corp. — $8 billion
0570 · China Traditional Chinese Medicine Holdings Co. Limited — $7 billion
2005 · SSY Group Limited — $7 billion
2575 · Xuanzhu Biopharmaceutical Co., Ltd. — $6 billion
4539 · Nippon Chemiphar Co., Ltd. — $6 billion
3613 · Beijing Tong Ren Tang Chinese Medicine Company Limited — $6 billion
INDV · Indivior Pharmaceuticals, Inc. — $5 billion
0719 · Shandong Xinhua Pharmaceutical Company Limited — $4 billion

← 6184 All “0-9” companies 6186 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.